134 related articles for article (PubMed ID: 37487754)
1. Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
Coustal C; Goulabchand R; Labauge P; Guilpain P; Carra-Dallière C; Januel E; Jeziorski E; Salle V; Viallard JF; Boutboul D; Fieschi C; Gobert D; Aladjidi N; Rullier P; Graveleau J; Piel-Julian M; Suarez F; Neven B; Mahlaoui N; Ayrignac X
Neurology; 2023 Oct; 101(15):e1560-e1566. PubMed ID: 37487754
[TBL] [Abstract][Full Text] [Related]
2. Two neurologic facets of CTLA4-related haploinsufficiency.
Ayrignac X; Goulabchand R; Jeziorski E; Rullier P; Carra-Dallière C; Lozano C; Portales P; Vincent T; Viallard JF; Menjot de Champfleur N; Rieux-Laucat F; Besnard C; Koenig M; Guissart C; Labauge P; Guilpain P
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32499327
[TBL] [Abstract][Full Text] [Related]
3. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.
Delalande S; de Seze J; Fauchais AL; Hachulla E; Stojkovic T; Ferriby D; Dubucquoi S; Pruvo JP; Vermersch P; Hatron PY
Medicine (Baltimore); 2004 Sep; 83(5):280-291. PubMed ID: 15342972
[TBL] [Abstract][Full Text] [Related]
4. Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
Angelino G; Cifaldi C; Zangari P; Di Cesare S; Di Matteo G; Chiriaco M; Francalanci P; Faraci S; Rea F; Romeo EF; Amodio D; Ursu GM; Bertocchini A; Accinni A; Crocoli A; Inserra A; Cozza R; Romano C; Licciardello M; Rinelli M; Dall'Oglio L; Cancrini C; De Angelis P; Finocchi A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1051-e1056. PubMed ID: 34034269
[TBL] [Abstract][Full Text] [Related]
5. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
6. Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
Mazzoni M; Dell'Orso G; Grossi A; Ceccherini I; Viola S; Terranova P; Micalizzi C; Guardo D; Massaccesi E; Palmisani E; Calvillo M; Fioredda F; Malattia C; Dufour C; Ravelli A; Miano M
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1168-e1172. PubMed ID: 33625086
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for CTLA-4 insufficiency.
Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
[TBL] [Abstract][Full Text] [Related]
8. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
9. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.
van Leeuwen EM; Cuadrado E; Gerrits AM; Witteveen E; de Bree GJ
J Clin Immunol; 2018 May; 38(4):464-467. PubMed ID: 29796761
[No Abstract] [Full Text] [Related]
11. Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.
Schindler MK; Pittaluga S; Enose-Akahata Y; Su HC; Rao VK; Rump A; Jacobson S; Cortese I; Reich DS; Uzel G
J Clin Invest; 2020 Oct; 130(10):5551-5561. PubMed ID: 32955488
[TBL] [Abstract][Full Text] [Related]
12. Relationship of CTLA4 and CD28 polymorphisms with lung involvement, HRCT findings and pulmonary function tests in Turkish patients with ankylosing spondylitis.
Karakose Okyaltırık F; Rezvani A; Turan S; Uysal Ö; Yakar F; Sozgen H; Ozkan NE; Akkoyunlu ME; Bayram M; Kutbay Ozcelik H; Sezer M; Guler M; Yaylım İ; Kart L
Clin Respir J; 2017 Sep; 11(5):593-601. PubMed ID: 26365494
[TBL] [Abstract][Full Text] [Related]
13. Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects.
Dhunputh C; Ducassou S; Fernandes H; Picard C; Rieux-Laucat F; Viallard JF; Lazaro E; Hermine O; Jouvray M; Machelard I; Lambilliotte A; Malphettes M; Moshous D; Neven B; Gauthier A; Garnier N; Leblanc T; Landman-Parker J; Leverger G; Aladjidi N
Blood; 2022 Jan; 139(2):300-304. PubMed ID: 34714911
[No Abstract] [Full Text] [Related]
14. Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis.
Hua LH; Donlon SL; Sobhanian MJ; Portner SM; Okuda DT
Spinal Cord; 2015 Jul; 53(7):520-5. PubMed ID: 25582716
[TBL] [Abstract][Full Text] [Related]
15. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
Khoury SJ; Rochon J; Ding L; Byron M; Ryker K; Tosta P; Gao W; Freedman MS; Arnold DL; Sayre PH; Smilek DE;
Mult Scler; 2017 Apr; 23(5):686-695. PubMed ID: 27481207
[TBL] [Abstract][Full Text] [Related]
16. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.
Lee S; Moon JS; Lee CR; Kim HE; Baek SM; Hwang S; Kang GH; Seo JK; Shin CH; Kang HJ; Ko JS; Park SG; Choi M
J Allergy Clin Immunol; 2016 Jan; 137(1):327-330. PubMed ID: 26478010
[No Abstract] [Full Text] [Related]
17. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment.
Christoforidis GA; Spickler EM; Recio MV; Mehta BM
AJNR Am J Neuroradiol; 1999 Apr; 20(4):655-69. PubMed ID: 10319978
[TBL] [Abstract][Full Text] [Related]
18. Pediatric stroke among Hong Kong Chinese subjects.
Chung B; Wong V
Pediatrics; 2004 Aug; 114(2):e206-12. PubMed ID: 15286258
[TBL] [Abstract][Full Text] [Related]
19. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.
Filippi M; Preziosa P; Meani A; Ciccarelli O; Mesaros S; Rovira A; Frederiksen J; Enzinger C; Barkhof F; Gasperini C; Brownlee W; Drulovic J; Montalban X; Cramer SP; Pichler A; Hagens M; Ruggieri S; Martinelli V; Miszkiel K; Tintorè M; Comi G; Dekker I; Uitdehaag B; Dujmovic-Basuroski I; Rocca MA
Lancet Neurol; 2018 Feb; 17(2):133-142. PubMed ID: 29275979
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
